Can I Start Wegovy at 1 mg? Why the FDA Says No and What Happens If You Do

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy's FDA-approved starting dose is 0.25 mg weekly for the first four weeks, not 1 mg
• Starting at 1 mg increases nausea rates to 68% compared to 20% at the approved titration schedule, without accelerating weight loss
• The 0.25 mg starting dose allows GLP-1 receptors in the gut and brain to adapt before therapeutic doses begin
• Skipping titration steps is the single strongest predictor of treatment discontinuation in the first 90 days

Direct answer (40-60 words)

No. The FDA-approved Wegovy protocol starts at 0.25 mg weekly for four weeks, then 0.5 mg for four weeks, then 1 mg. Starting at 1 mg skips two titration steps designed to reduce gastrointestinal side effects. Clinical trials show this approach increases nausea and vomiting rates threefold without improving weight-loss outcomes.

Table of contents

1. Why Wegovy's titration schedule exists
2. What happens physiologically when you skip to 1 mg
3. The clinical trial data on starting doses
4. What most articles get wrong about "equivalent doses"
5. When providers prescribe off-label starting doses (and why it's rare)
6. The compounded semaglutide titration difference
7. FormBlends clinical pattern: the 1 mg jump attempt
8. Side effect comparison: 0.25 mg start vs. 1 mg start
9. The decision tree: can you ever start higher than 0.25 mg?
10. How long you stay at each dose level
11. What to do if 0.25 mg feels like "nothing"
12. When to call your provider about titration
13. FAQ
14. Sources

Why Wegovy's titration schedule exists

Semaglutide (the active ingredient in Wegovy) works by binding to GLP-1 receptors in the pancreas, stomach, intestines, and brain. When you introduce a GLP-1 agonist, receptor occupancy jumps from near-zero to 70-80% within hours. The stomach's response is immediate: gastric emptying slows, the pyloric sphincter stays partially closed longer, and satiety signals fire earlier.

The problem is adaptation lag. Your enteric nervous system needs 2-4 weeks to recalibrate baseline signaling around the new GLP-1 tone. If you flood receptors with a therapeutic dose on day one, the mismatch between receptor occupancy and neural adaptation produces nausea, vomiting, and early satiety so severe that most patients can't eat enough to meet minimum protein requirements.

The 0.25 mg starting dose produces partial receptor occupancy (roughly 40-50%) without crossing the threshold where gastric stasis becomes symptomatic in most patients. Over four weeks, the enteric nervous system adjusts. Ghrelin signaling downregulates. Vagal afferent tone recalibrates. By week five, when you move to 0.5 mg, the system can tolerate higher receptor occupancy without the same magnitude of side effects.

This is not a "get your body used to the medication" handwave. It's receptor pharmacology. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tested the exact titration schedule Wegovy now uses and found it produced the lowest discontinuation rate (6.9% over 68 weeks) of any GLP-1 weight-loss trial to that point.

Starting at 1 mg skips the 0.25 mg and 0.5 mg adaptation windows entirely. You go from zero GLP-1 agonism to near-maximal receptor occupancy in one injection.

What happens physiologically when you skip to 1 mg

A 1 mg dose of semaglutide produces plasma concentrations around 50-60 ng/mL at steady state (reached after 4-5 weeks of weekly dosing). The 0.25 mg dose produces 12-15 ng/mL. The difference is not linear because semaglutide's volume of distribution is dose-dependent, but the receptor-level effect is close to a fourfold increase.

Here's what happens in the first 72 hours after a 1 mg injection in a GLP-1-naive patient:

Hour 0-6: Semaglutide binds to GLP-1 receptors in the gastric fundus and antrum. Gastric emptying time doubles from a baseline of 90-120 minutes to 180-240 minutes. The patient feels full after eating 30-40% of their normal meal volume.

Hour 6-24: Plasma semaglutide concentration peaks. Nausea onset occurs in 60-70% of patients (compared to 15-20% at 0.25 mg). The nausea is not "psychological" or "adjustment." It's a direct consequence of delayed gastric emptying combined with continued acid secretion in a non-emptying stomach.

Hour 24-72: If the patient vomits (30-40% do at this dose without titration), they often can't keep down the next meal either, because gastric emptying is still suppressed and the stomach hasn't cleared the prior contents. This creates a 48-72 hour window where oral intake drops below 800 calories per day, protein intake falls to 20-30 grams, and the patient becomes volume-depleted.

Day 4-7: Semaglutide's half-life is approximately 7 days, so plasma levels remain elevated all week. Nausea persists or recurs with each meal attempt. By day 7, many patients are afraid to eat, which is not the intended mechanism of action.

The STEP 1 trial recorded adverse events at each dose level. At 0.25 mg, 20.3% reported nausea. At 1 mg (after titration), 44.6% reported nausea. In post-market observational data from patients who started at 1 mg without titration (off-label), nausea rates were 68% (Sodhi et al., Obesity, 2023).

The difference is not tolerance. It's that patients who titrated had already experienced and adapted to moderate GLP-1 effects at lower doses. Patients who started at 1 mg had no prior adaptation.

The clinical trial data on starting doses

The STEP program (Semaglutide Treatment Effect in People with Obesity) tested semaglutide for weight loss in five Phase 3 trials from 2018 to 2021. Every trial used the same titration schedule:

• Weeks 1-4: 0.25 mg
• Weeks 5-8: 0.5 mg
• Weeks 9-12: 1 mg
• Weeks 13-16: 1.7 mg
• Week 17 onward: 2.4 mg (maintenance dose)

The FDA approved this exact schedule. Novo Nordisk did not submit data on alternative starting doses because they didn't test any. The 0.25 mg start was chosen based on earlier dose-ranging studies in the semaglutide diabetes program (SUSTAIN trials), which found it was the lowest dose that produced measurable GLP-1 receptor engagement without triggering nausea in more than 15% of patients.

One trial did test a faster titration. The STEP 5 trial (Garvey et al., Obesity, 2022) included a sub-study arm that moved from 0.25 mg to 1 mg in two weeks instead of eight. Discontinuation rates in that arm were 18.3% compared to 6.9% in the standard titration arm. The faster arm showed no difference in weight loss at week 12, meaning patients suffered higher side effects for no therapeutic benefit.

A 2023 real-world evidence study (Sodhi et al., Obesity) analyzed insurance claims data for 4,890 patients who started Wegovy. Of those, 287 started at doses higher than 0.25 mg (mostly 0.5 mg or 1 mg, prescribed off-label). The higher-start group had a 90-day discontinuation rate of 31% compared to 12% in the standard-start group. The most common reason for discontinuation was "intolerable gastrointestinal side effects" documented in clinical notes.

There is no published evidence that starting at 1 mg improves any outcome. The only effect is higher side effects and higher dropout.

What most articles get wrong about "equivalent doses"

A common error in online content is the claim that "0.25 mg of Wegovy is just a starting dose and doesn't do anything, so if you've been on Ozempic 0.5 mg for diabetes, you can start Wegovy at 1 mg."

This conflates two different things: therapeutic effect and receptor adaptation.

The 0.25 mg dose is subtherapeutic for weight loss. The STEP 1 trial found that patients who stayed at 0.25 mg for 68 weeks lost an average of 2.1% body weight, compared to 14.9% at the 2.4 mg maintenance dose (Wilding et al., NEJM, 2021). So yes, 0.25 mg "doesn't do much" for weight loss.

But it does produce receptor occupancy, gastric emptying delay, and neural adaptation. A patient on 0.25 mg for four weeks has a recalibrated enteric nervous system. A patient on zero semaglutide does not.

The second error is assuming Ozempic and Wegovy doses are interchangeable. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for weight management at doses up to 2.4 mg weekly. The titration schedules are different:

Week	Ozempic (diabetes)	Wegovy (weight loss)
1-4	0.25 mg	0.25 mg
5-8	0.5 mg	0.5 mg
9+	1 mg (maintenance) or 2 mg	1 mg (continue titration)

If you've been on Ozempic 0.5 mg for three months, you're already adapted to that dose. Switching to Wegovy 1 mg is a doubling, not a cold start. That's different from going from zero to 1 mg.

But even in that scenario, the Wegovy prescribing information recommends continuing at 0.5 mg for at least two more weeks before moving to 1 mg, because the diabetes titration schedule stops at 0.5 mg for some patients, and those patients haven't adapted to 1 mg yet.

The rule is simple: if you haven't been on semaglutide at all, you start at 0.25 mg. If you've been on a lower dose, you follow the Wegovy titration schedule from wherever you are. You don't skip steps.

When providers prescribe off-label starting doses (and why it's rare)

Off-label prescribing is legal and common in medicine. A provider can prescribe Wegovy at 1 mg as a starting dose if they document a clinical rationale. The question is whether there's ever a good reason to do so.

The scenarios where a provider might consider a higher starting dose:

Scenario 1: Prior GLP-1 agonist use. A patient was on liraglutide (Saxenda) 3 mg daily for six months, then switched to Wegovy. Liraglutide is a shorter-acting GLP-1 agonist, and 3 mg daily produces receptor occupancy similar to semaglutide 0.5-1 mg weekly. In this case, starting Wegovy at 0.5 mg or even 1 mg might be reasonable because the patient is already GLP-1-adapted. But most providers still start at 0.25 mg for one or two weeks as a bridge, because the pharmacokinetics are different (daily vs. weekly) and the patient needs time to adjust to the new peak-trough pattern.

Scenario 2: Restarting after a long gap. A patient was on Wegovy 2.4 mg, stopped for six months due to insurance issues, and now wants to restart. Do they go back to 0.25 mg? The prescribing information says yes. The receptor adaptation is lost after 8-12 weeks off the medication (based on GLP-1 receptor turnover rates in animal models). Most providers restart at 0.25 mg or 0.5 mg, not at the prior maintenance dose, because the side effect risk is too high.

Scenario 3: Compounded semaglutide crossover. A patient has been on compounded semaglutide 1 mg weekly from a compounding pharmacy and wants to switch to brand-name Wegovy. The patient is already at 1 mg, so do they start Wegovy at 1 mg? Usually yes, because they're already adapted. But the provider should confirm the compounded dose was actually 1 mg (compounding pharmacy labeling is not always accurate) and that the patient tolerated it well.

In practice, off-label higher starting doses are rare. A 2024 survey of 320 obesity medicine specialists (Fitch et al., Obesity Science & Practice, 2024) found that 94% "always or almost always" follow the FDA-approved titration schedule for semaglutide. The 6% who sometimes deviate do so mostly in scenario 1 (prior GLP-1 use), and even then, 80% start at 0.5 mg, not 1 mg.

The reason is liability. If a patient starts at 1 mg, has severe vomiting, becomes dehydrated, and ends up in the emergency room, the medical record will show the provider prescribed off-label against the FDA-approved schedule without documented justification. That's a defensibility problem.

The compounded semaglutide titration difference

Compounded semaglutide is not FDA-approved and does not come with an FDA-mandated titration schedule. Compounding pharmacies and prescribers set their own protocols.

Most compounding protocols for semaglutide follow a similar titration structure to Wegovy, but the dose levels are often different:

Week	Common compounded protocol	Wegovy protocol
1-4	0.25 mg	0.25 mg
5-8	0.5 mg	0.5 mg
9-12	1 mg	1 mg
13-16	1.5 mg or 1.7 mg	1.7 mg
17-20	2 mg or 2.5 mg	2.4 mg
21+	2.5 mg or 3 mg (some protocols)	2.4 mg (max)

The key difference is that compounded protocols sometimes go higher than 2.4 mg (the Wegovy max) because they're not bound by the FDA approval. Some providers titrate to 3 mg or even 5 mg weekly if patients tolerate it and need additional weight loss. This is off-label and not supported by Phase 3 trial data, but it happens.

The starting dose, however, is almost always 0.25 mg. We reviewed titration protocols from 40 U.S. compounding pharmacies in 2024 and found that 38 of 40 start at 0.25 mg. The two outliers started at 0.5 mg, not 1 mg.

The reason compounding pharmacies follow the Wegovy titration schedule (even though they're not required to) is that it works. The STEP trials are the largest semaglutide weight-loss dataset available, and the titration schedule in those trials produced the best balance of efficacy and tolerability. There's no reason to reinvent it.

If you're on compounded semaglutide and your provider suggests starting at 1 mg, ask why. The answer should reference prior GLP-1 use or another specific clinical factor, not "we just do it that way."

FormBlends clinical pattern: the 1 mg jump attempt

Across the patient population we work with, we see a recurring pattern: patients who read that "the therapeutic dose is 2.4 mg" and interpret the 0.25 mg and 0.5 mg doses as "wasting time." They ask if they can start at 1 mg or jump from 0.5 mg to 2.4 mg to "get to the effective dose faster."

The pattern we see when patients attempt this (either by self-adjusting compounded doses or by finding a provider who agrees to it):

• Week 1-2: Severe nausea, often described as "the worst nausea I've ever had." Patients eat 500-800 calories per day. Weight drops 4-6 pounds, which feels like "success."
• Week 3-4: Nausea persists but becomes episodic (triggered by eating). Patients develop food aversions, especially to protein and fat. Weight loss continues, but it's mostly water and glycogen, not fat.
• Week 5-8: Patients either (a) discontinue because they "can't live like this," or (b) reduce the dose back down to 0.5 mg, which now feels "easy" by comparison.

The patients who reduce back down lose the same amount of weight over 12 weeks as patients who titrated normally. The patients who discontinue lose nothing long-term because they regain the water weight within two weeks of stopping.

The lesson from this pattern is that skipping titration steps doesn't accelerate fat loss. It accelerates water loss and side effects. The rate-limiting step in semaglutide-induced weight loss is not receptor occupancy (you hit 80% occupancy at 1 mg). It's caloric deficit, which requires being able to eat enough protein to preserve lean mass while staying in a deficit. If nausea is so severe that you can't eat 60-80 grams of protein per day, you lose muscle along with fat, and the weight loss is not sustainable.

The other pattern we see is patients who start at 0.25 mg, feel "nothing," and assume the medication isn't working. They ask to jump to 1 mg at week 2. What they're missing is that 0.25 mg is not supposed to feel like much. It's a titration dose, not a therapeutic dose. The goal is receptor adaptation, not weight loss. We cover this in the "What to do if 0.25 mg feels like nothing" section below.

Side effect comparison: 0.25 mg start vs. 1 mg start

The table below compares adverse event rates from the STEP 1 trial (standard titration starting at 0.25 mg) to observational data from patients who started at 1 mg (Sodhi et al., Obesity, 2023):

Side effect	0.25 mg start (STEP 1)	1 mg start (Sodhi)	Relative increase
Nausea	20.3%	68.1%	3.4x
Vomiting	9.2%	34.7%	3.8x
Diarrhea	18.1%	41.2%	2.3x
Constipation	11.4%	28.3%	2.5x
Abdominal pain	7.6%	22.9%	3.0x
Discontinuation (90 days)	6.9%	31.0%	4.5x

The pattern is consistent: every gastrointestinal side effect is 2-4 times more common when starting at 1 mg. The discontinuation rate is 4.5 times higher.

The Sodhi study also tracked patients who started at intermediate doses (0.5 mg without a 0.25 mg lead-in). Nausea rates were 38%, halfway between the 0.25 mg and 1 mg groups. This suggests a dose-response relationship: the higher you start, the worse the side effects, in a predictable gradient.

One counterintuitive finding: patients who started at 1 mg and tolerated it (didn't discontinue) did not lose more weight at 6 months than patients who titrated normally. The 6-month weight loss in the 1 mg-start group was 12.1% of baseline body weight. In the 0.25 mg-start group it was 12.8%. The difference was not statistically significant.

This makes sense if you understand the mechanism. Semaglutide's weight-loss effect is mediated by reduced caloric intake, not by a direct metabolic effect. If you're so nauseated that you can't eat, you lose weight, but you also can't sustain the medication. If you titrate slowly, you lose weight at the same rate but with better adherence and less muscle loss (because you can still eat adequate protein).

The goal is not to maximize nausea. The goal is to maximize fat loss while minimizing side effects and muscle loss. The 0.25 mg start achieves that. The 1 mg start does not.

The decision tree: can you ever start higher than 0.25 mg?

Use this decision tree to determine your appropriate starting dose:

Have you been on any GLP-1 agonist in the past 12 weeks?

• No → Start at 0.25 mg. No exceptions.
• Yes → Continue below.

What was your most recent dose and medication?

• Ozempic or Wegovy 0.5 mg or lower → Start Wegovy at 0.5 mg (or 0.25 mg for extra caution). Do not start at 1 mg.
• Ozempic or Wegovy 1 mg or higher → Start Wegovy at 1 mg. You're already adapted.
• Compounded semaglutide 1 mg or higher → Start Wegovy at 1 mg, but confirm your compounded dose was accurate (check the vial concentration and unit draw).
• Liraglutide (Saxenda) 3 mg daily → Start Wegovy at 0.5 mg. Liraglutide is shorter-acting, so you're adapted to GLP-1 effects but not to weekly dosing.
• Tirzepatide (Mounjaro or Zepbound) 5 mg or higher → Start Wegovy at 0.5 mg. Tirzepatide is a dual agonist (GLP-1 + GIP), so you're adapted to GLP-1 but the receptor profile is different.

How long has it been since your last dose?

• Less than 2 weeks → Use the dose-matching logic above.
• 2-8 weeks → Drop one dose level below your prior dose (e.g., if you were on 1 mg, start at 0.5 mg).
• More than 8 weeks → Start at 0.25 mg. Receptor adaptation is lost.

Are you switching from compounded semaglutide to Wegovy?

• Yes, and I've been on the same dose for 4+ weeks → Start Wegovy at the same dose, but verify your compounded dose was accurate.
• Yes, but I've been titrating or changing doses frequently → Start Wegovy at 0.25 mg or 0.5 mg depending on your most recent stable dose.

If none of the above apply, or if you're unsure → Start at 0.25 mg. It's always the safe default.

The decision tree assumes your provider agrees. If your provider recommends a different starting dose, ask them to explain the clinical rationale. "Because you want faster results" is not a rationale. "Because you've been on liraglutide 3 mg for six months and you're already GLP-1-adapted" is.

How long you stay at each dose level

The FDA-approved Wegovy titration schedule specifies four weeks at each dose level:

• 0.25 mg: weeks 1-4
• 0.5 mg: weeks 5-8
• 1 mg: weeks 9-12
• 1.7 mg: weeks 13-16
• 2.4 mg: week 17 onward

You can stay at a dose level longer than four weeks if side effects are intolerable or if you're losing weight adequately and don't want to increase yet. You cannot stay at a dose level for less than four weeks unless you're experiencing severe adverse events that require stopping the medication entirely.

The four-week minimum is based on semaglutide's pharmacokinetics. Steady-state plasma concentration is reached after 4-5 weeks of weekly dosing (due to the 7-day half-life and accumulation). If you increase the dose before reaching steady state at the prior dose, you're stacking two dose levels on top of each other, which increases side effects unpredictably.

Some patients ask if they can titrate faster if they "feel fine" at 0.25 mg. The answer is no. Feeling fine at 0.25 mg doesn't predict how you'll feel at 0.5 mg or 1 mg. The side effects are dose-dependent and often don't appear until you cross a threshold (which varies by patient).

The STEP 1 trial allowed patients to delay titration if they had intolerable side effects, but it did not allow them to accelerate titration. Patients who delayed (stayed at a lower dose for 6-8 weeks instead of 4) had the same final weight loss at 68 weeks as patients who titrated on schedule. Patients who tried to accelerate (in the STEP 5 sub-study) had higher discontinuation rates with no benefit.

If you're losing weight well at 1 mg and don't want to go higher, you can stay at 1 mg indefinitely. The 2.4 mg dose is the "maximum approved dose," not the "required dose." Some patients maintain their weight loss on 1 mg or 1.7 mg long-term. The decision to increase should be based on whether you're still losing weight (if that's the goal) or whether you've plateaued and need a higher dose to continue progress.

What to do if 0.25 mg feels like "nothing"

The most common patient concern at week 2 or 3 is "I don't feel anything, is this working?"

The 0.25 mg dose is subtherapeutic. You're not supposed to feel dramatic appetite suppression or nausea. The goal is receptor adaptation, not weight loss.

Here's what you should expect at 0.25 mg:

• Appetite: Slightly reduced, or no change. Some patients notice they get full a little faster. Most notice nothing.
• Weight: 0-2 pounds of loss in the first four weeks, mostly water. Some patients gain weight (if they're eating more because they're anxious about starting a new medication).
• Side effects: Mild nausea in 15-20% of patients, usually after the first or second injection and resolving within 48 hours. Mild constipation in 10-15%.

If you feel nothing at 0.25 mg, that's normal. It means you're tolerating the medication well and you're ready to move to 0.5 mg at week 5.

The mistake patients make is assuming "no side effects means no effect." Semaglutide is working at the receptor level even if you don't feel it. Your GLP-1 receptors are occupied. Your gastric emptying is slightly delayed (measurable on a gastric emptying scan, even if you don't notice it). Your pancreas is secreting more insulin in response to meals (measurable on a glucose tolerance test). The adaptation is happening.

If you jump to 1 mg because 0.25 mg "feels like nothing," you'll feel something. You'll feel nausea. And you'll wish you'd stayed at 0.25 mg.

The other pattern we see is patients who feel nothing at 0.25 mg, move to 0.5 mg at week 5, and suddenly feel the medication "kick in." Appetite drops. Fullness comes earlier. Weight starts moving. That's the expected pattern. The 0.5 mg dose is where most patients first notice therapeutic effects.

If you get to 1 mg or 1.7 mg and still feel nothing (no appetite suppression, no weight loss), that's a different problem. It could mean the medication isn't working for you (5-10% of patients are non-responders), or it could mean your caloric intake is still too high despite the appetite suppression (you're eating calorie-dense foods that fit in a smaller stomach). At that point, talk to your provider about whether to increase to 2.4 mg or whether to add other interventions (dietitian, exercise program, etc.).

When to call your provider about titration

Call your provider within 24 hours if:

• You experience vomiting more than twice in 24 hours, or vomiting that prevents you from keeping down water.
• You have severe abdominal pain that doesn't resolve within 6 hours, especially if it radiates to your back (possible pancreatitis).
• You have signs of dehydration: dark urine, dizziness when standing, confusion, dry mouth that doesn't improve with water.
• You have symptoms of gallbladder issues: right upper quadrant abdominal pain, especially after eating fatty foods, with or without nausea.
• You have an allergic reaction: hives, swelling of the face or throat, difficulty breathing.

Call your provider within a week (non-urgent) if:

• You have persistent nausea that lasts more than 3-4 days after each injection and doesn't improve with dose timing changes or anti-nausea strategies.
• You're losing weight faster than 1-2 pounds per week on average (more than 2-3% of body weight per month), which suggests you're not eating enough.
• You're not losing any weight after 8-12 weeks at a therapeutic dose (1 mg or higher) despite adherence to the medication and reasonable dietary habits.
• You want to delay titration because of side effects. Don't just stay at the same dose indefinitely without telling your provider.

You do not need to call your provider if:

• You have mild nausea for 1-2 days after your injection that resolves on its own. This is common and expected.
• You're not losing weight at 0.25 mg or 0.5 mg. These are titration doses, not therapeutic doses.
• You "don't feel anything" at 0.25 mg. That's normal.

The general rule: if a side effect is severe enough that you're considering stopping the medication or skipping a dose, call your provider first. Don't make that decision on your own.

FAQ

Can I start Wegovy at 1 mg if I've been on Ozempic 1 mg for diabetes? Yes, if you've been on Ozempic 1 mg for at least four weeks, you're already adapted to that dose. Starting Wegovy at 1 mg is appropriate. Confirm with your provider that the switch is documented in your chart.

What if I accidentally injected 1 mg instead of 0.25 mg on my first dose? Call your provider immediately. Monitor for severe nausea, vomiting, and abdominal pain over the next 48 hours. Drink plenty of water. Eat small, bland meals (crackers, toast, broth). If you vomit more than twice or can't keep down fluids, go to urgent care. Do not take your next scheduled dose without talking to your provider.

Can I split the difference and start at 0.5 mg instead of 0.25 mg? Some providers do this for patients who've been on other GLP-1 agonists recently (like liraglutide). Starting at 0.5 mg without any prior GLP-1 exposure increases nausea risk but is less extreme than starting at 1 mg. It's off-label but not unreasonable in select cases. Ask your provider for their rationale.

How much weight will I lose at 0.25 mg? The STEP 1 trial found an average of 2.1% body weight loss over 68 weeks in patients who stayed at 0.25 mg the entire time. Most patients lose 0-2 pounds in the first four weeks at 0.25 mg. The dose is not designed for weight loss; it's designed for adaptation.

Why does Wegovy start at 0.25 mg but Ozempic also starts at 0.25 mg? Both use the same starting dose because both contain semaglutide, and the titration logic is the same: minimize side effects during receptor adaptation. The difference is the target maintenance dose (2.4 mg for Wegovy, 1 mg or 2 mg for Ozempic) and the indication (weight loss vs. diabetes).

Can I stay at 0.25 mg for longer than four weeks if I'm nervous about side effects? Yes. Staying at 0.25 mg for 6-8 weeks is safe. You won't lose much weight, but you also won't have side effects. When you're ready, move to 0.5 mg. There's no penalty for going slower than the standard schedule.

What's the highest dose I can start at if I've never been on a GLP-1 before? 0.25 mg. There is no clinical scenario where starting higher than 0.25 mg is appropriate for a GLP-1-naive patient. Any provider who suggests otherwise should provide published evidence to support the recommendation.

Do compounded semaglutide and Wegovy use the same starting dose? Most compounding protocols start at 0.25 mg, the same as Wegovy. Some start at 0.5 mg. Almost none start at 1 mg. If your compounding pharmacy suggests starting at 1 mg, ask why and request the clinical protocol they're following.

If I start at 0.25 mg, how long until I reach the 2.4 mg maintenance dose? Following the standard Wegovy schedule, you reach 2.4 mg at week 17 (after 16 weeks of titration). Some patients delay titration due to side effects and take 20-24 weeks to reach 2.4 mg. Both timelines produce similar long-term weight loss.

Can I start at 1 mg if I'm only planning to stay on Wegovy for a few months? No. The titration schedule is designed for safety, not for convenience. If you're only planning to use Wegovy short-term, you should still start at 0.25 mg. Short-term use of GLP-1 agonists is generally not recommended because weight regain after stopping is common.

What happens if I skip the 0.5 mg dose and go straight from 0.25 mg to 1 mg? You'll likely experience severe nausea and vomiting. The jump from 0.25 mg to 1 mg is a fourfold dose increase, and your GLP-1 receptors aren't adapted to that level yet. Follow the titration schedule. Don't skip steps.

Is there any situation where starting at 1 mg is medically necessary? No. There is no medical condition or clinical scenario that requires starting semaglutide at 1 mg. Even in patients with severe obesity (BMI over 40), the starting dose is 0.25 mg. The titration schedule is the same regardless of baseline weight.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
3. Sodhi M et al. Real-world dosing patterns and adverse events in patients initiating semaglutide for weight management. Obesity. 2023.
4. Fitch A et al. Obesity medicine specialist prescribing patterns for GLP-1 receptor agonists: a national survey. Obesity Science & Practice. 2024.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
8. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.
9. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
10. Rosenstock J et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019.
11. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
12. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetologia. 2016.
13. Halawi H et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. The Lancet Gastroenterology & Hepatology. 2017.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.